Nadia Harbeck

77PUBLICATIONS
430CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthCancer diagnosisCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (77)

|Sep 04, 2026
Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.

|Jul 28, 2026
A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence.

|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

|Nov 21, 2025
Multimodal Artificial Intelligence Model From Baseline Histopathology Adds Prognostic Information for Distant Recurrence Assessment in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Daniel Kates-Harbeck, Hans Kreipe, Oleg Gluz

|Nov 03, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial.

Monika Graeser, Oleg Gluz, Peter Schmid

Pageof 13

Frequent Collaborators

9 joint publications

Sherko Kümmel

8 joint publications

Seock-Ah Im

8 joint publications

Miguel Martin

7 joint publications

Monika K Graeser